GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Anakinra (KINERET)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Kineret

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Renal interval change does not substitute the adult RA dose

The official label considers alternate-day administration of the prescribed dose below CrCl 30. The adult RA 100 mg dose is not the weight-based NOMID/DIRA dose.

Before applying: Retain indication and population when changing the interval. The separate official retrieval does not repair the failed RX page attempt.

Also check: Renal interval change does not substitute the adult RA dose

Official source

KINERET - official renal dosing and indication distinction

Product / population
Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.
Renal measure
CrCl <30 mL/min, including ESRD.

Separate DailyMed retrieval; the KINERET RX click remains failed.

Renal dosing, restrictions and evidence limits

For severe impairment or ESRD (CrCl <30), consider the prescribed dose every other day. For adult RA this is 100 mg every other day. NOMID/DIRA use the individually prescribed weight-based dose, not an automatic adult 100 mg substitution. Hemodialysis/CAPD removed <2.5% in the PK study; no inferred post-dialysis supplement is added. Assess neutrophils before treatment, monthly for three months, then quarterly through one year. Full infection and immunization precautions remain necessary.

Source revision: October 2025 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d74915-6606-4570-9c52-c4001d3177de

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

KINERET - official renal dosing and indication distinction

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.

Renal method: CrCl <30 mL/min, including ESRD.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Kineret

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Subcutaneous anakinra; prescribed dose depends on the labeled indication and population.

Renal method: CrCl, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population or indication

Renal interval change does not substitute the adult RA dose

The official label considers alternate-day administration of the prescribed dose below CrCl 30. The adult RA 100 mg dose is not the weight-based NOMID/DIRA dose.

How to use this: Retain indication and population when changing the interval. The separate official retrieval does not repair the failed RX page attempt.

KINERET - official renal dosing and indication distinction

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeKINERET - official renal dosing and indication distinctionGlobalRPh RX List - Kineret
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/kineret-drug/

Product and population scope

Subcutaneous anakinra; prescribed dose depends on the labeled indication and population.

RDM33-SCOPE-anakinra-kineret-C1 · Source section: Exact product identity and selected populationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

KINERET - official renal dosing and indication distinction

Open original reference

Open / share this exact local source

DailyMed / Swedish Orphan Biovitrum · Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.

Renal method: CrCl <30 mL/min, including ESRD.
Source date: October 2025
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For severe impairment or ESRD (CrCl <30), consider the prescribed dose every other day. For adult RA this is 100 mg every other day. NOMID/DIRA use the individually prescribed weight-based dose, not an automatic adult 100 mg substitution. Hemodialysis/CAPD removed <2.5% in the PK study; no inferred post-dialysis supplement is added. Assess neutrophils before treatment, monthly for three months, then quarterly through one year. Full infection and immunization precautions remain necessary.

RDM42-official-anakinra-kineret-f743b567cb-C1 · Source locator: Sections 2.1-2.4, 5.7, 12.3

Source-specific limits

Separate DailyMed retrieval; the KINERET RX click remains failed.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d74915-6606-4570-9c52-c4001d3177de
Retrieved
2026-09-07
Exact label title
KINERET - official renal dosing and indication distinction
DailyMed Set ID
d9d74915-6606-4570-9c52-c4001d3177de
Labeler
Swedish Orphan Biovitrum
Label revision
October 2025
Renal-function method
CrCl <30 mL/min, including ESRD.
Source date/version
October 2025
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
806fad7eb8cffa79eba7976b7574f920065d1ccbc54c149e46e0f0f05d200d94
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Kineret

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Subcutaneous anakinra; prescribed dose depends on the labeled indication and population.

Renal method: CrCl, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

When CrCl is below 30 mL/min, including end-stage renal disease, consider giving the prescribed dose every other day rather than daily. This is an interval-extension recommendation, not an instruction to halve each daily dose. Hemodialysis and continuous ambulatory peritoneal dialysis remove less than 2.5% of the administered dose.

RDM33-rxlist-anakinra-kineret-C1 · Source locator: Dosage and administration: renal impairment; clinical pharmacology: renal impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/kineret-drug/
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
fb3738f872670c6f83602443bb8409de8dab60483db36c8dafc2e0e6cfc128f7

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/kineret-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
40756af72a3da500a9eeedb97e1ca3ff79d564004e2527ab37d0ab00feed229b
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report